8-K: Sonendo Secures Amendment to Credit Agreement, Averting Near-Term Amortization Payments

Sonendo, Inc. has entered into an amendment to its credit agreement, deferring and waiving certain amortization payments contingent upon successful equity financings.

Summary

• Sonendo, Inc. has amended its credit agreement with Perceptive Credit Holdings III, LP, effective February 28, 2025.
• The amendment defers the February 28, 2025 amortization payment to March 31, 2025.
• It waives the February amortization payment and subsequent payments due on or before September 30, 2025, subject to conditions.
• Amortization payments after September 30, 2025 are waived until March 31, 2026, also subject to conditions.
• These deferrals and waivers are contingent upon near-term equity financings and capital-raising transactions with minimum gross proceed requirements.
• If the Amendment No. 4 Equity Offering Transaction is completed by March 31, 2025, the deferred February amortization payment will be waived, and no amortization payments will be required during the Amendment No. 4 Initial Deferral Period.
• If the Amendment No. 4 Equity Offering Transaction is not completed by March 31, 2025, the deferred February amortization payment will be due on March 31, 2025, and the Borrower shall make monthly amortization payments in the amount of $900,000.00.
• If the Amendment No. 4 Equity Offering Transaction is completed on or prior to March 31, 2025 and the subsequent Financing Transaction is completed on or before September 30, 2025, no amortization payments will be required during the Subsequent Financing Transaction Deferral Period.
• Following the consummation of the Subsequent Financing Transaction, the Borrower shall make mandatory prepayments to the Lender in amounts equal to (x) 100% of the amount of net proceeds resulting from the Subsequent Financing Transaction in excess of $10,000,000 and up to $15,000,000, and (y) 50% of net proceeds resulting from the Subsequent Financing Transaction in excess of $15,000,000.
• The amendment also includes a waiver related to the 'going concern' qualification in the audit for the fiscal year ending December 31, 2024.
• The minimum Revenue table set forth in Section 10.02 of the Prior Credit Agreement shall be deemed to be amended and restated (automatically and without any further action or condition) in its entirety if the Amendment No. 4 Equity Offering Transaction is consummated on or prior to March 31, 2025.

Sentiment

Score: 5

Explanation: The amendment provides short-term relief but relies on future equity raises, indicating ongoing financial pressure. The waiver of the 'going concern' qualification is a positive, but the overall situation suggests moderate concern.

Positives

• The amendment provides Sonendo with increased financial flexibility by deferring and potentially waiving near-term amortization payments.
• The waiver of the 'going concern' qualification in the 2024 audit removes a potential red flag for investors.
• The company has the opportunity to improve its financial position through equity financings.

Negatives

• The deferral and waiver of amortization payments are contingent on raising capital through equity financings, which may dilute existing shareholders.
• If the equity financings are not completed by the specified deadlines, the original amortization schedule, or a modified version with $900,000 monthly payments, will resume.
• The company's reliance on waivers and amendments to its credit agreement may indicate underlying financial challenges.

Risks

• Failure to secure the required equity financings could result in the resumption of amortization payments, straining the company's cash flow.
• The need for repeated amendments to the credit agreement may signal deeper financial instability.
• The equity financings could be dilutive to existing shareholders.
• The minimum Revenue table set forth in Section 10.02 of the Prior Credit Agreement shall be deemed to be amended and restated (automatically and without any further action or condition) in its entirety if the Amendment No. 4 Equity Offering Transaction is consummated on or prior to March 31, 2025.

Future Outlook

The company's ability to meet its financial obligations is dependent on securing equity financings. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws.

Industry Context

Many small-cap companies in the medical device sector rely on debt financing to fund operations and growth. Amendments to credit agreements are not uncommon, especially for companies facing financial headwinds. The ability to secure such amendments often depends on the company's prospects and the lender's confidence in its long-term viability.

Comparison to Industry Standards

• It's difficult to directly compare Sonendo's situation without knowing the specifics of its financial performance relative to its peers.
• However, companies like Dentsply Sirona and Envista Holdings, which are larger players in the dental equipment and supplies market, generally have stronger balance sheets and access to more favorable financing terms.
• Smaller companies often face challenges in securing favorable debt terms and may need to rely on equity financing or strategic partnerships to support their growth.

Stakeholder Impact

• Shareholders face potential dilution from equity financings.
• Employees' job security could be affected by the company's financial performance.
• Suppliers and creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• Sonendo needs to secure the Amendment No. 4 Equity Offering Transaction by March 31, 2025.
• Sonendo needs to secure the Subsequent Financing Transaction by September 30, 2025.
• The company must meet the amended revenue targets outlined in the agreement.

Key Dates

Keywords

credit agreement, amortization, equity financing, waiver, Sonendo, debt, Perceptive Credit Holdings, capital raise